secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0000950170-24-083928
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genentech terminates migoprotafib collaboration; Relay loses future milestones
------------------------------------------------------------------------------

- Genentech terminated without cause; effective 180 days after July 11, 2024.
- Relay had received $121.8M total ($75M upfront + $45M milestones + R&D costs).
- No further milestone or royalty payments due after termination date.
- Relay regains full rights to migoprotafib (SHP2 inhibitor) and all associated data.
- Termination removes expected future payments; drug development status uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024083928/0000950170-24-083928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024083928/rlay-20240711.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-083928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer